The company said it will use the proceeds for general corporate purposes, such as the repayment of debt, working capital, and possible acquisitions.
The company announced during its Q4 earnings call that it had acquired Paradigm Diagnostics and Viomics to fill out its expertise in cancer diagnostics.
The firm reported that test volumes for its Cologuard colorectal cancer screening test rose 63 percent year over year.
Natera discussed its cancer and transplant rejection testing businesses, while Exact Sciences explained how it will benefit from its Genomic Health acquisition.
Test volume for its Cologuard test was up 63 percent year over year, while test volume for Genomic Health's Oncotype DX jumped 14 percent.
Of the 39 deals included in the analysis, only three exceeded $100 million in value, with the rest having significantly smaller price tags or prices that were not disclosed.
Developers pointed to some success, but they also noted that more at-home tests need to demonstrate higher levels of performance and affordability.
Gainers in the index outpaced the decliners 19 to nine, and the index outpaced the Dow Jones Industrial Average and Nasdaq Biotechnology Index but lagged the Nasdaq.
The company released data showing that its panel detects early-stage liver cancer with 71 percent sensitivity compared to 25 percent for the standard test.
Exact argues that JHU has no basis to demand any royalties on sales of Cologuard because the test doesn't use any patents the university licensed to the company.